Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Janux Therapeutics, Inc. Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs July 17, 2023 From Janux Therapeutics, Inc. Via Business Wire Tickers JANX Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference February 14, 2023 From Janux Therapeutics, Inc. Via Business Wire Tickers JANX Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors December 27, 2022 From Janux Therapeutics, Inc. Via Business Wire Tickers JANX Janux Therapeutics to Present at Upcoming Investor Conferences in November November 22, 2022 From Janux Therapeutics, Inc. Via Business Wire Tickers JANX Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights November 10, 2022 From Janux Therapeutics, Inc. Via Business Wire Tickers JANX Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer October 12, 2022 From Janux Therapeutics, Inc. Via Business Wire Tickers JANX Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources September 23, 2022 From Janux Therapeutics, Inc. Via Business Wire Tickers JANX Janux Therapeutics Appoints Winston Kung to Board of Directors September 22, 2022 From Janux Therapeutics, Inc. Via Business Wire Tickers JANX Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September August 31, 2022 From Janux Therapeutics, Inc. Via Business Wire Tickers JANX Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights August 09, 2022 From Janux Therapeutics, Inc. Via Business Wire Tickers JANX Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer May 31, 2022 From Janux Therapeutics, Inc. Via Business Wire Tickers JANX Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights May 10, 2022 From Janux Therapeutics, Inc. Via Business Wire Tickers JANX Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results March 18, 2022 From Janux Therapeutics, Inc. Via Business Wire Tickers JANX Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference January 05, 2022 From Janux Therapeutics, Inc. Via Business Wire Tickers JANX Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results November 09, 2021 From Janux Therapeutics, Inc. Via Business Wire Tickers JANX Janux Therapeutics to Present Virtually at Upcoming Investor Conferences November 08, 2021 From Janux Therapeutics, Inc. Via Business Wire Tickers JANX Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors September 09, 2021 From Janux Therapeutics, Inc. Via Business Wire Tickers JANX Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference September 07, 2021 From Janux Therapeutics, Inc. Via Business Wire Tickers JANX Janux Therapeutics Reports Second Quarter 2021 Financial Results August 10, 2021 From Janux Therapeutics, Inc. Via Business Wire Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares June 15, 2021 From Janux Therapeutics, Inc. Via Business Wire Tickers JANX Janux Therapeutics Announces Pricing of Initial Public Offering June 11, 2021 From Janux Therapeutics, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.